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SHORT COMMUNICATION
The value of high dose tamoxifen in postmenopausal breast cancer
patients progressing on standard doses: A pilot study
S.M. Watkins
Department ofMedical Oncology, Lister Hospital, Stevenage, Herts SGJ 4AB, UK.
Tamoxifen is an extremely useful drug in the management of
advanced breast cancer. Although it produces remission in
only one third of patients, the remarkably low incidence and
mild nature of side effects makes it a very acceptable mode
of treatment.
Results of attempts to increase response rates by using
higher initial doses have been disappointing, (Bratherton
et al., 1984; Ortiz de Taranco et al., 1979; Rose et al., 1982)
although in one series (Ortiz de Taranco et al., 1979) there
were substantially higher rates of stable disease and lower
rates of progressive disease in patients receiving 40mg
compared with those on 20mg daily. Furthermore, there
have been occasional case reports of initially responding
patients who subsequently relapsed on standard doses of
tamoxifen, then going into a second remission when the dose
was doubled (Manni & Arafah, 1981; Westerberg et al.,
1976). From these observations it appeared that some
patients might benefit from achieving blood levels of
tamoxifen higher than the usually accepted therapeutic
range. Therefore the present pilot study was undertaken to
assess the effect of a dose of 90mg daily in patients who had
progressive disease on doses of 20-40mg daily.
Post-menopausal patients with advanced breast cancer
progressing after treatment for at least 10 weeks with
tamoxifen at doses of 20-40mg daily (standard dose), were
considered for trial on the high dose. Patients with rapidly
progressive disease were excluded and given chemotherapy
instead. Seriously ill patients with a life expectancy of less
than 3 months were also excluded. Twenty-eight patients
aged 49 to 83 (mean 64) were included. They were 5 months
to 35 years post-menopausal (mean 15 years). Six had had
prior treatment with other endocrine manipulations, and 9
had had chemotherapy. Standard dose tamoxifen was given
for a minimum of 10 weeks, and responses were assessed
according to UICC criteria (Hayward et al., 1978). On
standard dose tamoxifen there had been 10 cases of
progressive disease; four patients went into complete
remission, there were 4 partial remissions, and 10 with stable
disease: all these 18 patients subsequently developed
progressive disease. When the patients showed evidence of
primary or secondary progression, the dose of tamoxifen was
increased to 30mg tds. Patients were reviewed at least once a
month by SMW. X-rays were independently assessed by a
consultant radiologist. Initially abnormal chest X-rays and
liver function tests were repeated every month and skeletal
X-rays every 6-8 weeks, or sooner if there was any clinical
indication.
The tamoxifen used in this study was Nolvadex (ICI plc,
UK). Serum levels of tamoxifen were measured before and 8
weeks after starting the high dose. The tamoxifen levels were
assayed by ICI Pharmaceuticals using the HPLC method.
Aliquots of serum (1.0ml) were spiked with internal
standard (N-dipropyl analogue of tamoxifen). Following the
addition of 1.0M phosphate buffer, pH 7 (1.0ml) the samples
were extracted with 1.5% (v/v) amyl alcohol in hexane
(5ml). After tumble shaking for 1 h and centrifugation to
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separate the phases, a portion (4.5ml) of the organic phase
was transferred to a clean tube and reduced to dryness at
room temperature under a stream of oxygen-free nitrogen.
The dry residue was redissolved in HPLC eluent (500Il).
Aliquots of the reconstituted extracts (typically 50pl) were
separated on a 5p Zorbax ODS column (0cm x4.6mm)
eluted at a flow rate of 1.5mlmin-1, with tetrahydrofuran-
acetonitrile-water-ammonia (sp. gr. 0.88) 15:70:15:0.4 by
volume. The tamoxifen was detected in the column eluent by
its uv absorption at 240nm.
Response was assessed according to UICC criteria
(Hayward et al., 1978). There were two partial remissions
lasting 5 and 8 months, and 15 patients with stable disease
lasting from three to 19 months (median 5 months). Many of
these stable patients had considerable symptomatic relief on
the higher dose. There was no correlation between response
to standard dose and high dose tamoxifen.
With regard to the various sites of disease, the best
response rates were seen in primary lesions and lymph node
metastases (complete plus partial regression 3/8 and 5/8
respectively). Stable disease was frequently seen in soft tissue
lesions (8/11 plus 1/11 partial remission). Bony lesions also
appeared to remain static for long periods (12/19 stable
disease), but in only one patient was overall stable disease
assessed on bony lesions alone.
Mild side-effects (lethargy, tiredness, loss of taste and hot
flushes) were reported in 4 patients, but no-one withdrew
from the trial on this account. There was no evidence of
retinopathy.
The steady state serum concentrations of tamoxifen rose
when patients took the higher dose, but levels varied widely,
and there was no correlation between response and serum
levels of the drug (Figure 1).
This study shows that many post-menopausal women with
advanced breast cancer, progressing in spite of treatment
with standard dose tamoxifen, benefit from receiving the
drug in high doses (90mg daily). Although there were only
occasional remissions, there was stabilisation of disease
(frequently with symptomatic improvement) in over half the
patients, and as side-effects were minimal, this resulted in
good quality life, often for many months. A comparable
observation was made by Stewart et al. (1982) who showed
that although increasing the dose of tamoxifen from 20mg
to 40mg daily in patients with progressive disease did not
produce objective responses, yet a quarter of these patients
had stable disease for up to 15 months.
In our patients, the best responses to high dose tamoxifen
were seen in primary tumours and lymph node metastases;
however, the numbers are too small for statistical analysis.
Stable disease was observed in two thirds of bony metas-
tases, although in only one patient (number 14) was overall
stable disease assessed on bony lesions alone. Radiological
changes in metastatic bone cancer are usually slow and
hence difficult to interpret. Indeed, it has been suggested that
in some cases of apparently static bone disease, there may
actually be some tumour response, in spite of the absence of
discernable radiological evidence of healing (Coleman &
Rubens, 1987).
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Figure 1 Blood levels of tamoxifen in patients on standard dose
and high dose tamoxifen. Correlation of steady state values with
dose in individual patients and response at the higher dose. (@)
Progressive disease; (0) stable disease; (E]) partial response.
Although there does appear to be a change in the rate of
progression of disease in some patients after dose increases,
in our patients, as in the series of Bratherton et al. (1984),
there was no correlation between serum levels and clinical
benefit.
The mechanism of the improved efficacy of tamoxifen at
high doses is not clear. The oestrogen-reversible inhibitory
effect of tamoxifen on cell proliferation in ER-positive cell
lines in vitro is clearly seen at the low concentrations of
tamoxifen corresponding to the usual therapeutic steady
state blood levels achieved on standard doses of the drug
(Reddel et al., 1985).
However, oestrogen-irreversible cytotoxicity has been
demonstrated in vitro in both ER-positive and ER-negative
cell lines at high concentrations of tamoxifen (albeit higher
than the blood levels achieved in this study), suggesting that
under these circumstances growth inhibition and cytotoxicity
may be mediated by mechanisms independent of the
anti-oestrogen effect (Reddel et al., 1985). There is in vitro
evidence that tamoxifen and its metabolites in high
concentrations inhibit protein kinase C, an enzyme which
mediates signals for cellular proliferation (O'Brian et al.,
1986). On the other hand, Gulino et al. (1986) felt that
protein kinase C inhibition was unimportant and have
suggested that the interaction between anti-oestrogen and
calmodulin may be responsible for mediating drug-induced,
oestrogen-independent inhibition of breast cancer cell
growth, possibly by causing intracellular accumulation of
cAMP. The relevance of these in vitro findings to the
observations made in the present study remain to be
elucidated.
Although in our study, increasing the dose of tamoxifen
to 90mg daily produced only two partial remissions,
nevertheless, the high incidence and sometimes prolonged
duration of stable disease with minimal side-effects and good
quality of life, makes this a useful and highly acceptable
approach in cases of primary and secondary failure of
tamoxifen treatment, and well worth trying before switching
to other forms of endocrine therapy or chemotherapy, all of
which have more serious side-effects.
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